Alice Blue Home
URL copied to clipboard

Trending News

Aurobindo Pharma shares jump after arm signs key deal to market biosimilars in EU

CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, entered a marketing and distribution agreement with STADA to sell two EMA-approved biosimilars in select EU countries.
Aurobindo Pharma shares rise after EU biosimilars marketing deal

Introduction

Leading Indian biosimilars company signs agreement with a European healthcare firm to market and distribute two EMA-approved biosimilars in select EU territories, including France and Germany.

Alice Blue Image

Also Read: Waaree Energies approves ₹3,900 Cr capex for glass manufacturing facility; stock gains 3%

Share price movement of Aurobindo Pharma

On March 27, 2026, Aurobindo Pharma Ltd opened at ₹1,330.90, up 1.79% from its previous close of ₹1,307.70. The stock reached a high of ₹1,330.90 (1.79%) and a low of ₹1,296.40 (-0.86%). By 12:12 PM, it traded at ₹1,312.00, a 0.33% increase, with a market cap of ₹76,201.17 crore.

CuraTeQ Signs EU Biosimilars Deal

CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, has signed a marketing and distribution agreement with STADA Arzneimittel AG. The deal covers select European Union territories, including France and Germany.

Under the agreement, STADA will market and distribute two EMA-approved biosimilars developed by CuraTeQ. New brand names will be registered for each biosimilar, aiming to expand market reach and revenue growth in EU markets.

Stock performance of Aurobindo Pharma for period of 1 week, 6 months, and 1 year

Aurobindo Pharma Ltd delivered a 1-week return of 1.27%, a 6-month return of 20.0%, and a 1-year return of 12.3%.

Alice Blue Image

Also Read: HDFC Life receives ₹126 Cr tax demand, ₹45 Cr interest added

Shareholding pattern of Aurobindo Pharma

ParticularsDec 2025Sep 2025Jun 2025
Promoter51.80%51.80%51.80%
FII14.00%14.20%14.40%
DII27.70%27.60%26.90%
Public6.60%6.40%6.90%

About Aurobindo Pharma

Aurobindo Pharma Ltd (NSE: AUROPHARMA) manufactures and markets active pharmaceutical ingredients, generic drugs, and related services, serving domestic and international markets with a diverse pharmaceutical portfolio.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs

Q: Why is Aurobindo Pharma Ltd share price rising today?

A: Aurobindo Pharma Ltd share price rises after CuraTeQ Biologics, its subsidiary, signs EU marketing and distribution deal for two biosimilars.

Q: What is Aurobindo Pharma Ltd’s main business focus?

A: Aurobindo Pharma Ltd focuses on manufacturing and marketing active pharmaceutical ingredients, generic drugs, and related pharmaceutical services globally.

Q: What are the 52-week high and low of Aurobindo Pharma Ltd stock?


A: The 52-week high of Aurobindo Pharma Ltd stock is ₹1,330.90, and the 52-week low is ₹994.35.

Submit the form, and get to know how you scored!!!

Gainers & Losers

Read More News

*T&C apply